Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved Aerinaze opve - jer risiciene til behandling af symptomerne ved sæsonbundet høfeber ledsaget af stoppet næse.
The Committee for Medicinal Products for Human Use (CHMP) decided that Aerinaze’ s benefits are greater than its risks for the symptomatic treatment of seasonal allergic rhinitis when accompanied by nasal congestion.